MetaCap

Gelteq (GELS) vs NeuroSense Therapeutics (NRSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeuroSense Therapeutics is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GELS-51.78%NRSN-66.49%
+3%-34%-70%
Oct 7, 20261 yearNov 20, 2026
GELS-48.18%NRSN-65.03%
+3%-33%-68%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GELS versus NRSN key metrics
MetricGELSNRSN
Share price$0.2701$1.28
Market cap$3.11M$3.19M
1-day change-3.74%+1.59%
EPS (TTM)$-0.44$-47.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-6.65M$-11.13M
52-week high$2.01$24.80
52-week low$0.255$1.10
Distance from 52-week high-86.56%-94.84%
Analyst consensus—strong_buy
Avg. price target upside—+7503.91%
Average volume2.85M31.57K
Shares outstanding11.51M2.49M
Employees717
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Gelteq

GELS stock →

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About NeuroSense Therapeutics

NRSN stock →

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

GELS vs NRSN FAQ

Which is bigger, Gelteq or NeuroSense Therapeutics?

NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $3.19M compared with $3.11M for Gelteq (GELS).

Are Gelteq and NeuroSense Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons